Related Experiment Video
Updated: Dec 13, 2025
12:18
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
23.4K
[Experience with daptomycin in a tertiary pediatric hospital]
María T Rosanova1, Norma Sberna2, Claudia Sarkis1
1Servicio de Control Epidemiológico e Infectología, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina.
Summary
Daptomycin is a safe and effective treatment for children with serious infections, including those caused by MRSA. It offers an alternative when vancomycin fails or causes toxicity.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Antimicrobial Therapy
Background:
- Vancomycin is the standard for MRSA infections but has limitations.
- Poor tissue penetration, renal toxicity, and monitoring needs prompt alternatives.
- Daptomycin emerges as a potential alternative for pediatric infections.
Purpose of the Study:
- To evaluate the safety and effectiveness of daptomycin in pediatric patients.
- To assess daptomycin's role in treating infections resistant to conventional therapies.
Main Methods:
- Retrospective analysis of children with microbiologically confirmed infections treated with daptomycin.
- Inclusion criteria: documented infections treated with daptomycin.
Main Results:
- Most common infections: endocarditis (32%), bacteremia (25%), sepsis (14%).
- MRSA was the predominant pathogen (64%).
- Daptomycin used due to treatment failure (61%) or vancomycin toxicity (39%). Favorable response in 79% of patients. Adverse events were infrequent.
Conclusions:
- Daptomycin shows promising efficacy and a favorable safety profile in pediatric patients.
- It serves as a viable option for complex pediatric infections, especially those involving MRSA.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
131
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
191
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
191
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
176
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
176
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
148
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
148
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
113
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
113
01:29Drug Dosing: Infants and Children
153
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
153